Article information
Article
These are the options to access the full texts of the publication Revista Clínica Española (English Edition)
Member
Si es usted socio de FESEMI siga los siguientes pasos:
Diríjase desde aquí a la web de la >>>https://www.fesemi.org/publicaciones/revista-clinica/noticias<<< e inicie sesión mediante el formulario que se encuentra en la barra superior, pulsando sobre el candado.
Deslice el cursor hacia abajo hasta la sección "PUBLICACIONES" y pinche en "Revista Clínica Española":
>>>https://www.fesemi.org/publicaciones/revista-clinica/noticias<<<
Purchase
References
[1]
B. Cao, Y. Wang, D. Wen, W. Liu, J. Wang, G. Fan, et al.
Trial of lopinavir-ritonavir in adults hospitalized with severe covid-19.
N Engl J Med, (2020),
[2]
V.C.C. Cheng, S.K.P. Lau, P.C.Y. Woo, K.Y. Yuen.
Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection.
Clin Microbiol Rev, 20 (2007), pp. 660-694
[3]
Z. Song, Y. Xu, L. Bao, L. Zhang, P. Yu, Y. Qu, et al.
From SARS to MERS, thrusting coronaviruses into the spotlight.
Viruses, 11 (2019), pp. E59
[4]
C. Jun, L. Yun, X. Xiuhong, L. Ping, L. Feng, L. Tao, et al.
Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia.
Chin J Infect Dis, 38 (2020),
[5]
Results from a single center, open label, randomized, and controlled trial conducted at Shanghai Public Health Clinical Center (SPHCC) of darunavir and cobicistat (DRV/c) in treating laboratory-confirmed 30 COVID-19 patients showed that DRV/c was not effective. Available in: https://www.jnj.com/lack-of-evidence-to-support-darunavir-based-hiv-treatments-for-coronavirus. [Accessed 6 April 2020].
